United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Our Collaborations
Contact Us
Newsroom
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra™
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Pipeline & Data
Breast Radiation Score
Next Generation Cologuard
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Cancerguard™
Our Expertise
Cancerguard™ Science
Multi-Cancer Early Detection Thought Leadership
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Environmental, Social, and Governance (ESG)
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts in:
Investor Relations
November 01, 2023
Exact Sciences Announces Third-Quarter 2023 Results
September 12, 2023
Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
August 01, 2023
Exact Sciences Announces Second-Quarter 2023 Results
June 21, 2023
Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
June 20, 2023
Next Generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent specificity, Raising the Bar in Non-invasive Screening
May 09, 2023
Exact Sciences Announces First Quarter 2023 Results
February 21, 2023
Exact Sciences Announces Fourth Quarter 2022 Results
January 08, 2023
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
November 03, 2022
Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
October 24, 2022
Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting
April 28, 2017
Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
October 03, 2016
What Cologuard's Inclusion in HEDIS Means
1
2
3